Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00894478
Other study ID # 1000013137
Secondary ID
Status Completed
Phase N/A
First received May 6, 2009
Last updated September 9, 2013
Start date May 2009
Est. completion date May 2012

Study information

Verified date September 2013
Source The Hospital for Sick Children
Contact n/a
Is FDA regulated No
Health authority Canada: Ethics Review Committee
Study type Observational

Clinical Trial Summary

Focal cortical dysplasia is one of the most common lesions responsible for medically refractory epilepsy in the pediatric population. In patients with medically intractable epilepsy, surgery is the only treatment that will lead to seizure freedom. The outcome of epilepsy surgery is worse in patients when there is no lesion identified on routine structural MRI, also known as MRI-negative partial epilepsy. Diffusion tensor imaging (DTI), a novel MRI technique, can be used to evaluate the integrity of the microstructure of the white matter, even when the white matter appears normal on routine MRI.


Description:

The aims of this study are firstly to identify DTI abnormalities in the white matter of children with MRI-negative partial epilepsy and MRI-visible FCD compared to normal controls; and secondly to determine if the location of DTI identified abnormalities correlate with the epileptogenic zone as defined using magnetoencephalography (MEG) dipole clusters. Our hypotheses are firstly DTI can demonstrate the anatomic delineation of white matter abnormalities in MRI-negative partial epilepsy and the alteration in DTI indices are similar in MRI-negative partial epilepsy and MRI-visible FCD, which is the positive control; and secondly the anatomical location of DTI identified abnormalities correlate with the epileptogenic zone as defined by MEG dipole clusters. The long-term goal of this study is to improve detection of subtle lesions in children with MRI-negative partial epilepsy so as to improve the surgical outcome of these patients who undergo epilepsy surgery for seizure control.


Recruitment information / eligibility

Status Completed
Enrollment 64
Est. completion date May 2012
Est. primary completion date May 2012
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 6 Years to 18 Years
Eligibility Inclusion Criteria:

MRI negative partial epilepsy group:

- Patients diagnosed with partial epilepsy according to the International League Against Epilepsy (ILAE) standard [53]

- MRI study reported as normal

- Age ranging from 6-18 years (DTI indices alter with myelination and the changes are most marked from birth to 4 years of age)

MRI-visible FCD group:

- Patients diagnosed with partial epilepsy according to the ILAE standard [53]

- Visual assessment of MRI demonstrates one or more features of FCD

- Cortical thickening

- Alteration in sulci and gyri pattern, including deep sulci

- Blurring of gray-white matter transition

- T2 signal prolongation of the cortex and subcortical white matter

- High T1 signal in the cortex

- Age ranging from 6-18 years (DTI indices alter with myelination and the changes are most marked from birth to 4 years of age)

Normal controls:

- Subjects with no history of neurological diseases

- Age ranging from 6-18 years (most children under the age of 6 years are unable to tolerate the MR examination without general anesthesia or sedation).

- No requirement of general anesthesia or sedation

Exclusion Criteria:

- Subjects with contraindications for MR imaging (i.e. retained foreign bodies, implants)

- Subjects with claustrophobia

- Controls with a prior history of traumatic brain injury, neurological disorder, cerebral palsy, developmental delay or learning disability

- Controls who require general anesthesia or sedation

Study Design

Observational Model: Cohort, Time Perspective: Cross-Sectional


Intervention

Procedure:
Diffusion Tensor Imaging (DTI)
MR and DTI: MRI and DTI will be done using 3.0T Philips MR scanner (Philips Medical Systems, Best, The Netherlands) using an eight channel head coil. DTI and axial 3D T1 will be performed on patients and controls. DTI will be performed using single shot diffusion-weighted echo planar imaging, b=1000s/mm2 and 15 noncollinear directions (TR/TE=10,000/60 ms, slice thickness=2mm, field of view=22cm, matrix=112x112, NEX=2) Axial 3D T1 (TR/TE=4.9/2.3 ms, slice thickness=1 mm, field of view = 24 cm, matrix=220x220, NEX=1) Patients will have additional sequences (axial and coronal T2, proton density and FLAIR) as part of their clinical scan
Magnetoencephalography
MEG will be performed using a whole-head Omega 151-channel gradiometer system (VSM MedTech, Port Coquitalam, BC, Canada). At least 15 2-minute periods of spontaneous data will be recorded with a sampling rate for data acquisition of 625Hz, a bandpass filter of 10 to 70 Hz and a notch filter of 60 Hz.

Locations

Country Name City State
Canada The Hospital for Sick Children Toronto Ontario

Sponsors (1)

Lead Sponsor Collaborator
The Hospital for Sick Children

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Identify DTI changes in the white matter of children with MRI-negative partial epilepsy and MRI-visible FCD using voxel-by-voxel analysis of FA and MD maps compared to normal controls. 1 timepoint; immediately after MRI/DTI No
Secondary Determine if the lobar location of abnormal FA and MD correlate with the lobar location of MEG defined epileptogenic zone in MRI-negative partial epilepsy and MRI-visible FCD. 1 timepoint; immediately after MRI/DTI No
See also
  Status Clinical Trial Phase
Withdrawn NCT00982787 - Safety and Anticonvulsant Efficacy of Passiflora Incarnata Extract in Patients With Partial Epilepsy Phase 2
Completed NCT00898560 - Effect of Repeat Administration of Eslicarbazepine Acetate on the Pharmacokinetics of a Combined Oral Contraceptive Phase 1
Recruiting NCT01735032 - Multimodal Imaging in Pre-surgical Evaluation of Epilepsy N/A
Completed NCT01090934 - Localizing the Epileptogenic Zone With High Resolution Electroencephalography N/A
Terminated NCT00391534 - EXTENT: EXtended Tolerability and Efficacy of a Novel Formulation of Oxcarbazepine in a Trial in Partial Epilepsy Phase 3
Terminated NCT01496612 - Buspirone Therapy for Localized Epilepsy Phase 2
Completed NCT00900237 - Study to Evaluate Pharmacokinetics and Tolerability of Multiple Doses of Eslicarbazepine Acetate and Oxcarbazepine Phase 1
Recruiting NCT04903314 - Dose-Escalation Study of Cenobamate (YKP3089) in Pediatric Subjects With Partial-Onset Seizures Phase 1
Completed NCT01373190 - Thermographic Examination of Skin Temperatures in Individuals With Focal Onset Epilepsy N/A
Recruiting NCT03478852 - Investigating Epilepsy: Screening and Evaluation
Recruiting NCT01273129 - Surgery as a Treatment for Medically Intractable Epilepsy
Completed NCT00001666 - Transcranial Magnetic Stimulation for the Treatment of Poorly Controlled Partial Epilepsy N/A
Completed NCT00001932 - Serotonin Receptors in Seizure Disorders N/A
Completed NCT00908349 - Safety and Tolerability of OXC XR as Adjunctive Therapy in Subjects With Refractory Partial Epilepsy Phase 3
Completed NCT02076698 - Deep Brain Stimulation of the Anterior Nucleus of the Thalamus in Epilepsy Phase 3
Completed NCT00706160 - Language Mapping in Patients With Epilepsy
Completed NCT01397968 - Efficacy and Safety of YKP3089 in Subjects With Treatment Resistant Partial Onset Seizures Phase 2
Completed NCT01866111 - A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Trial of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures Phase 2
Completed NCT00957047 - Efficacy and Safety Study of BIA 2-093 in Combination With Other Anti-Epileptic Drugs to Treat Partial Epilepsy Phase 3
Terminated NCT01281956 - PRX-00023 Therapy in Localization-Related Epilepsy Phase 2